Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04040192 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 620
- Enrollment target
NCT04040192 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 620 participants.
The verdict
NCT04040192, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 620 participants
- Enrollment target
Study Summary
This study will evaluate crisaborole therapy once daily (QD) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (BID) treatment.
Interventions
- DRUG Vehicle
- DRUG Crisaborole 2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2019-09-12 |
| Est. Completion | 2022-01-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04040192
The ClinicalTrials.gov registry entry for NCT04040192 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT04040192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04040192 about?
NCT04040192 is a clinical study titled "A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis". This study will evaluate crisaborole therapy once daily (QD) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (BID) treatment.
What is the current status of trial NCT04040192?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2019-09-12. Estimated completion is 2022-01-19.
What interventions are being tested in trial NCT04040192?
The interventions under investigation include: Vehicle (DRUG), Crisaborole 2% (DRUG).
Who is sponsoring clinical trial NCT04040192?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.